CLARET ASSET MANAGEMENT Corp Acquires New Shares in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Share on StockTwits

CLARET ASSET MANAGEMENT Corp acquired a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,617 shares of the specialty pharmaceutical company’s stock, valued at approximately $207,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Signaturefd LLC increased its holdings in Jazz Pharmaceuticals by 56.3% in the second quarter. Signaturefd LLC now owns 200 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 72 shares during the last quarter. Commonwealth Equity Services LLC increased its holdings in Jazz Pharmaceuticals by 2.8% in the second quarter. Commonwealth Equity Services LLC now owns 3,338 shares of the specialty pharmaceutical company’s stock valued at $475,000 after purchasing an additional 92 shares during the last quarter. MAI Capital Management increased its holdings in Jazz Pharmaceuticals by 2.2% in the second quarter. MAI Capital Management now owns 4,364 shares of the specialty pharmaceutical company’s stock valued at $622,000 after purchasing an additional 96 shares during the last quarter. MML Investors Services LLC increased its holdings in Jazz Pharmaceuticals by 4.4% in the second quarter. MML Investors Services LLC now owns 2,593 shares of the specialty pharmaceutical company’s stock valued at $370,000 after purchasing an additional 109 shares during the last quarter. Finally, Confluence Investment Management LLC grew its stake in Jazz Pharmaceuticals by 2.9% in the second quarter. Confluence Investment Management LLC now owns 4,243 shares of the specialty pharmaceutical company’s stock valued at $605,000 after acquiring an additional 118 shares during the period. Institutional investors and hedge funds own 87.62% of the company’s stock.

NASDAQ:JAZZ opened at $118.67 on Friday. Jazz Pharmaceuticals PLC has a 1 year low of $113.52 and a 1 year high of $165.66. The company has a current ratio of 3.71, a quick ratio of 3.52 and a debt-to-equity ratio of 0.58. The stock has a market cap of $6.72 billion, a price-to-earnings ratio of 9.70, a PEG ratio of 1.46 and a beta of 1.11. The stock has a 50-day moving average price of $127.58 and a two-hundred day moving average price of $133.79.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.16 by $0.49. The company had revenue of $534.13 million during the quarter, compared to analysts’ expectations of $507.23 million. Jazz Pharmaceuticals had a return on equity of 27.72% and a net margin of 32.99%. Jazz Pharmaceuticals’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.49 earnings per share. Sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 13.44 earnings per share for the current year.

A number of research firms have issued reports on JAZZ. Wells Fargo & Co reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 14th. Barclays boosted their target price on Jazz Pharmaceuticals from $164.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Mizuho set a $148.00 target price on Jazz Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday, July 3rd. ValuEngine raised Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. Finally, Oppenheimer set a $176.00 target price on Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, September 26th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $168.43.

In other news, CEO Bruce C. Cozadd sold 500 shares of the company’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $130.00, for a total transaction of $65,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Paul Treacy sold 4,371 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $137.40, for a total value of $600,575.40. The disclosure for this sale can be found here. Insiders have sold 5,597 shares of company stock valued at $764,057 over the last ninety days. 4.30% of the stock is owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Story: Balance Sheet

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CLARET ASSET MANAGEMENT Corp Acquires New Shares in Jazz Pharmaceuticals PLC
CLARET ASSET MANAGEMENT Corp Acquires New Shares in Jazz Pharmaceuticals PLC
Crossmark Global Holdings Inc. Sells 4,288 Shares of Progressive Corp
Crossmark Global Holdings Inc. Sells 4,288 Shares of Progressive Corp
Clarus Wealth Advisors Decreases Stock Position in AutoZone, Inc.
Clarus Wealth Advisors Decreases Stock Position in AutoZone, Inc.
Rio Tinto plc ADR  Shares Sold by Crossmark Global Holdings Inc.
Rio Tinto plc ADR Shares Sold by Crossmark Global Holdings Inc.
iShares US Real Estate ETF  Shares Sold by Clarus Wealth Advisors
iShares US Real Estate ETF Shares Sold by Clarus Wealth Advisors
CMH Wealth Management LLC Has $3.05 Million Stake in JPMorgan Chase & Co.
CMH Wealth Management LLC Has $3.05 Million Stake in JPMorgan Chase & Co.


© 2006-2019 Ticker Report